



## Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

Jun 10, 2025

Company to host webcast on Thursday, June 12 at 6:00 pm ET

HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company's Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held in Glasgow, Scotland. Abstracts will be available on the meeting website Thursday, June 12<sup>th</sup> at 6:01 pm ET/ Friday, June 13<sup>th</sup> at 12:01 am CEST. Celldex will host a webcast on Thursday, June 12<sup>th</sup> at 6:00 pm ET to discuss the data.

### Phase 2 CSU 76 Week Efficacy and Tolerability Data

#### **Company Webcast and Conference Call**

**Date & Time:** Thursday, June 12<sup>th</sup> at 6:00 pm ET/11:00 pm BST

**Presenters:** Company representatives and Martin Metz, MD, Professor, Department of Dermatology and Allergy, Head of Translation Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and lead investigator for the Phase 2 CSU study

**Webcast Access:** Please visit the Events section on the Investor Relations page of [Celldex's website](#) to register for the webcast. Parties interested in participating via telephone may register [here](#) to receive the dial-in numbers and unique PIN to seamlessly access the call.

#### **EAACI Presentation Session**

**Date & Time:** Friday, June 13<sup>th</sup> at 9:12 am BST/4:12 am ET

**Late Breaking Oral Presentation 100227:** *Sustained Disease Control Following Withdrawal of Barzolvolimab in Patients with Chronic Spontaneous Urticaria*

**Presenting Author:** Ana Maria Giménez-Arnau, MD, PhD, Associate Professor of Dermatology Autonomous University and Pompeu Fabra University

### Phase 2 CSU 52 Week Angioedema Data

**EAACI Session Date & Time:** Saturday, June 14<sup>th</sup> at 3:48 pm BST/10:48 am ET

**Oral Presentation 000588:** *Treatment with Barzolvolimab Leads to Sustained Improvement in Angioedema in Chronic Spontaneous Urticaria (CSU) patients: Results from 52 Weeks of Treatment*

**Presenting Author:** Martin Metz, MD, Professor, Department of Dermatology and Allergy, Head of Translation Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and lead investigator for the Phase 2 CSU study

#### **About Celldex**

Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit [www.celldex.com](http://www.celldex.com).

#### **Company Contact**

Sarah Cavanaugh  
Senior Vice President, Corporate Affairs & Administration  
(508) 864-8337  
[scavanaugh@celldex.com](mailto:scavanaugh@celldex.com)

Patrick Till  
Meru Advisors  
(484) 788-8560  
[ptill@meruadvisors.com](mailto:ptill@meruadvisors.com)



Source: Celldex Therapeutics, Inc.